Sintesis Asam 2-(2-(n-(2,6-diklorofenil)-4 fluorobenzamida)fenil)asetat sebagai Kandidat Obat Penghambat COX (siklooksigenase)

Triodora Hutahuruk; Ayik Rosita; Ika Oktavianawati

Sintesis Asam 2-(2-(n-(2,6-diklorofenil)-4 fluorobenzamida)fenil)asetat sebagai Kandidat Obat Penghambat COX (siklooksigenase)

Triodora Hutahuruk Fakultas Farmasi Universitas Jember
Ayik Rosita Fakultas Farmasi Universitas Jember
Ika Oktavianawati Fakultas Farmasi Universitas Jember

Abstract

Sodium diclofenac is a non selectif NSAID that used as an inflammatory, analgesic, and antipyretic. Several experiment about compound as a derivate sodium diclofenac has
been synthesized for reduce side effect. 2-(2-(N-(2,6-dichlorophenyl)-4-fluorobenzamido)phenil)acetat acid (N4FND) is derivate of sodium diclofenac that synthesized for development of drugs. The target compound has been synthesized by benzoylation reaction between sodium diclofenac with 4-fluorobenzoylchloride. And then, the target compound has been purified using Coloumn Chromatography. The isolate was identified using 1HNMR 400 MHz and KBr FTIR. Spectra of of 1HNM 00 MHz and KBr FTIR showed that 2-(2-(N-(2,6-dichlorophenyl)-4-fluorobenzamido)phenil)acetat acid was successfully synthesized. Pure product compound form yellowish white crystals with melting point 165-1670C.

Published

2014-05-14

How to Cite

HUTAHURUK, Triodora; ROSITA, Ayik; OKTAVIANAWATI, Ika. Sintesis Asam 2-(2-(n-(2,6-diklorofenil)-4 fluorobenzamida)fenil)asetat sebagai Kandidat Obat Penghambat COX (siklooksigenase). Pustaka Kesehatan, [S.l.], v. 2, n. 2, p. 215-220, may 2014. ISSN 2721-3218. Available at: <https://jurnal.unej.ac.id/index.php/JPK/article/view/1088>. Date accessed: 22 nov. 2024.

Citation Formats

Issue

Vol 2 No 2 (2014)

Section

Articles

e-Journal Pustaka Kesehatan has CC-BY-SA or an equivalent license as the optimal license for the publication, distribution, use, and reuse of scholarly work. Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.